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IL-10 receptor blockadeThe Env glycoproteins gp120 and gp41 are used in humoral immunity-based vaccines against human
immunodeﬁciency virus (HIV-1) infection. One among many obstacles to such a vaccine is the structural
defenses of Env glycoproteins that limit their immunogenicity. For example, gp120 mannose residues can
induce immunosuppressive responses in vitro, including IL-10 expression, via mannose C-type lectin
receptors on antigen-presenting cells. Here, we have investigated whether mannose removal alters gp120
immunogenicity in mice. Administering demannosylated gp120 (D-gp120) in the TH2-skewing adjuvant
Alum induced ∼50-fold higher titers of anti-gp120 IgG, compared to unmodiﬁed gp120. While the IgG
subclass proﬁle was predominantly TH2-associated IgG1, Abs of the TH1-associated IgG2a and IgG3 subclasses
were also detectable in D-gp120 recipients. Immunizing with D-gp120 also improved T-cell responses. Giving
an IL-10 receptor blocking MAb together with unmodiﬁed gp120 in Alum increased the anti-gp120 IgG titer,
implicating IL-10 as a possible mediator of auto-suppressive responses to gp120.
© 2009 Elsevier Inc. All rights reserved.IntroductionThe envelope glycoproteins (Env) of human immunodeﬁciency
virus type 1 (HIV-1) are the focus of attempts to make a preventative
vaccine based, wholly or in part, on virus-neutralizing antibodies
(NAbs) (Monteﬁori et al., 2007). The most common immunization
method for Env vaccines involves administering soluble monomeric
gp120 or trimeric gp140 proteins, in a suitable adjuvant (Pantophlet
and Burton, 2006). This approach generally leads to the induction of
signiﬁcant titers of antibodies (Abs) against the immunizing antigen
(e.g., anti-gp120 binding Abs), but little or no NAbs against primary
isolates (Burton et al., 1991; Gilbert et al., 2005; Graham et al., 1998).
Underlying this problem are the structural defenses that have evolved
in Env proteins, which hinder the induction of NAbs and then restrict
their binding to the functional Env trimer, notably by shielding critical
epitopes (Grundner et al., 2004; Pantophlet and Burton, 2006).
However, there are other adverse aspects of Env immunogenicity that
may also impede the development of a NAb-based vaccine. For
example, although Abs can clearly be induced by gp120 vaccines,y 801, Weill Cornell Medical
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ll rights reserved.these proteins are not particularly immunogenic compared to many
other antigens (Pantophlet and Burton, 2006); relatively high gp120
concentrations are required to induce even binding antibodies
(Connor et al., 1998; Gilbert et al., 2005; Graham et al., 1998;
Grundner et al., 2005); the titers of these Abs decay fairly rapidly,
necessitating repeat boosting (Connor et al., 1998); and a signiﬁcant
minority of gp120 vaccinees never develop any detectable Ab
responses (Connor et al., 1998; Grundner et al., 2005). Moreover the
IgG response to gp120 is unusually TH2-polarized in both mice and
humans (Gorse et al., 1999; Jankovic et al., 1997). We have suggested
that at least some of these observations reﬂect the existence of Env-
induced immunosuppressive responses (Shan et al., 2007).
HIV-1 gp120 is a biologically active protein that can activate signal
transduction via multiple cell surface receptors such as CD4, CCR5 or
CXCR4, andmannose C-type lectin receptors (MCLRs)when it is added
in the μg/ml concentration range to various types of human cells in
vitro (Pantophlet and Burton, 2006). It is uncertain which, if any, of
these signaling events is relevant during HIV-1 infection in vivo,
because the concentrations of soluble gp120 and/or virions in
lymphoid tissues are hard to quantify (Klasse and Moore, 2004).
However, during vaccination, 0.1–1 mg of gp120 or gp140 proteins is
typically added in a small volume, directly into a muscle. The resulting
concentrations are likely to easily exceed those that trigger signaling
Fig. 1. Biochemical properties of demannosylated gp120. Preparations of gp120 were
assessed for (A) m.wt. changes, (B) the presence of α(1-2,3,6)-mannosidase using a
non-reducing 4–12% Bis–Tris NuPage gel. The D-gp120 preparation shown in (A) is from
batch #2 after CHT column puriﬁcation.
Table 1
Measurement of mannosidase activity.
Sample Condition Enzyme activity
(units/ml; %)
Demannosylation reaction mixture Fresh enzyme added
to gp120 (time zero)
1.420 (100%)
Enzyme (mock treated) Treated similarly to that
of D-gp120 batch #1
0.212 (14.9%)
D-gp120 batch #1 Before CHT puriﬁcation 0.045 (3.2%)
D-gp120 batch #2 After CHT puriﬁcation ND
Enzyme (inactivated) Boiling (100 °C, 10 min) ND
The activity of α(1-2,3,6)-mannosidase in various preparations was determined
according to the manufacturer's recommendation (see Materials and methods). The
activity of enzyme added to the reaction mixture at the start of the demannosylation
procedure was 14.2 U/mg gp120 protein or 1.42 U/ml. This was deﬁned as 100%, for
normalization purposes. ND, Not detectable; i.e., below the assay detection limit of
0.01 U/ml.
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mayhappenduring the initial stages of a host response to Env vaccines.
We have recently described the effects of gp120 on human,
immature monocyte-derived dendritic cells (MDDCs) in vitro (Shan et
al., 2007). The immunosuppressive cytokine IL-10 is induced by some
gp120 proteins (e.g., from HIV-1 JR-FL) in cells from ∼50% of normal
donors. Furthermore, MDDC maturation is adversely affected, inde-
pendently of the IL-10 response, impeding their ability to stimulate
CD4+ T-cell proliferation (Shan et al., 2007). These responses to gp120
are dependent on interactions of mannose moieties on its N-linked
glycans with MCLRs on the MDDC surface including, but perhaps not
limited to, DC-SIGN; they can be prevented by treating gp120 with a
mannosidase (Shan et al., 2007).
Here, we have investigated whether mannosidase digestion affects
the immunogenicity of gp120 in mice, including the TH2 bias of the
IgG response. To do this, we immunized mice with JR-FL gp120
preparations that contained or lacked mannose moieties, in either
Quil A or Alum adjuvant. We found that demannosylated gp120 (D-
gp120), compared with to unmodiﬁed gp120 (M-gp120), induced
signiﬁcantly higher titers of gp120-binding antibodies when adminis-
tered in Alum adjuvant, but not in Quil A. In marked contrast to the
IgG1-dominated TH2 antibody response to M-gp120, the response to
D-gp120 in Alum also involved the TH1-associated subclasses IgG2a
and IgG3. Furthermore, D-gp120 was also a superior immunogen for
T-cell responses. Because gp120 induces IL-10 expression in vitro,
albeit with human MDDCs, we investigated whether IL-10 might play
a role in suppressing the immunogenicity of gp120 under in vivo
conditions. Accordingly, we administered a blocking MAb to the IL-10
receptor at the time of M-gp120 immunization, and found that this
procedure also increased the titers of anti-gp120 binding antibodies.
As expected for immunogens based on monomeric gp120, neither
demannosylation nor the use of the IL-10 blocking MAb induced NAbs
at detectable titers.
Results
Biochemical and antigenic characterization of demannosylated gp120
We have shown that JR-FL gp120 activates IL-10 production by
human MDDCs in vitro, as well as impairing their maturation, as aresult of interactions between its mannose moieties and an MCLR
(Shan et al., 2007). In view of the role played by dendritic cells in
priming immune responses in vivo, we wished to see whether gp120
that had been treated with a mannosidase enzyme to eliminate these
effects might be a better immunogen. We have shown elsewhere that
mannosidase treatment eliminates the mannose-dependent interac-
tions of JR-FL gp120 with MAb 2G12 and DC-SIGN, but without
compromising CD4-binding or conformational epitopes for other
MAbs (Sanders et al., 2002; Shan et al., 2007). Here, we show the
biochemical and antigenic properties of two different batches of
demannosylated gp120 (D-gp120) that were used to immunize mice.
These studies compared D-gp120 with unmodiﬁed gp120 and with
gp120 that had been treated exactly as D-gp120, but without exposure
to mannosidase (M-gp120).
Mannosidase digests were carried out as described in theMaterials
and methods section. Demannosylation of gp120 reduced its
molecular weight by ∼10 kDa, judged by migration on a 4–12% Bis–
Tris NuPage gel (Fig. 1A). A ∼10 kDa reduction corresponds to the
removal of ∼55 mannose residues, which are each of 0.18 kDa
(Sanders et al., 2002). Batch #1 of D-gp120 contained some residual
mannosidase enzyme, which is visible as two bands of 66 kDa and
44 kDa on a Bis–Tris NuPage gel (Fig.1B). However, an enzyme activity
assay showed that the contaminant enzyme had minimal activity
(Table 1). Thus, the residual mannosidase activity in D-gp120 batch #1
was ∼3% of what was present in the reaction mix at the start of the
process (deﬁned as 100%). For comparison, the residual enzyme
activity was ∼15% when mannosidase was processed under identical
conditions to D-gp120 batch #1 but without gp120 present (Table 1).
Unless otherwise speciﬁed, D-gp120 from batch #1 was used in
subsequent studies.
Because of concerns about whether the residual mannosidase in D-
gp120 batch #1 might have had an inﬂuence on the outcome of
immunogenicity experiments (see below), perhaps by acting as an
adjuvant, we devised a procedure to remove the enzyme prior to
immunization of mice. To do this, the standard D-gp120 preparation
was passed through a ceramic hydroxylapatite (CHT) column. The
resulting D-gp120 batch #2 preparation was essentially free of
mannosidase, as assessed using both the Bis–Tris NuPage gel system
(Fig. 1A) and an enzyme activity assay (Table 1). The endotoxin levels
of both batches of D-gp120 were below the detection limit of the LAL
test (0.06 EU/ml).
We conﬁrmed that mannosidase digestion was functionally
effective by showing that both D-gp120 preparations were unable to
bind MAb 2G12 (Fig. 2, and data not shown). The epitopes for other
anti-gp120 Abs on D gp120 were, however, unaltered. Thus HIVIG,
CD4-IgG2 and MAbs b6, b12, 15e, A32, 17b (+sCD4), 447 52D and
F425 B4e8 all bound comparably to the mannosidase-treated and
control gp120s (Fig. 2, and data not shown). Hence mannose removal
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eliminating the 2G12 epitope. Any differences in immune responses
to the unmodiﬁed and mannose-depleted proteins would probably
not be attributable to changes in antibody epitope accessibility. The
antigenic proﬁle of themannosidase-free (batch #2) preparation of D-
gp120 was similar to that of batch #1 (data not shown).
Enhanced IgG response in mice immunized with demannosylated gp120
in Alum adjuvant but not in Quil A
To explore the immunogenicity of D-gp120, we ﬁrst conducted a
pilot experiment in which BALB/c mice were primed and then twice
boosted with gp120, M-gp120 or D-gp120 (batch #1). Previous
studies have indicated that the murine immune response to gp120 is
strongly TH2 polarized (Daly et al., 2005; Jankovic et al., 1997), so we
used both a TH1-polarizing and a TH2-polarizing adjuvant, Quil A
(Fernando et al., 1998) and Alum (Pollock et al., 2003) respectively, to
explore whether any effect of gp120 demannosylation was adjuvant-
dependent.
Compared to gp120 and M-gp120, the serum gp120-binding IgG
titers were elevated in mice immunized with D-gp120 in Alum
(Fig. 3A). The mean titers were increased by 30-fold at the 4-week
time-point (p=0.0417 vs. gp120 or M-gp120, one-tailed Student's
t test), and by 6-fold at 6 weeks (p=0.0041 for D-gp120 vs.
gp120 or M-gp120, one-tailed Student's t test). As expected, there
were no differences between the anti-gp120 responses to gp120
and M-gp120 at any time-point (week 4, p=0.4716; week 6,
p=0.2825, one-tailed Student's t test).
Anti-gp120 titers were 1000- and 100-fold greater at 4 and
6 weeks, respectively, when Quil A was used as the adjuvant,
compared to Alum (Fig. 3B). In contrast to the beneﬁcial effect of
gp120 mannose removal seen with Alum adjuvant, there were no
signiﬁcant differences in the anti-gp120 titers between mice immu-
nized with gp120, M-gp120 or D-gp120 in Quil A (Fig. 3B).
To assess the reproducibility of these observations and to extend
them, we repeated the pilot experiments with C57BL/6 mice instead
of BALB/c. In these C57BL/6 experiments, we omitted the gp120 arm,
M-gp120 serving as the control for D-gp120 using both alum and
Quil A adjuvants. Higher anti-gp120 IgG titers were again observed in
the D-gp120 (Alum) recipients, compared to M-gp120 (Fig. 4). Thus,
mannose removal consistently renders gp120 more immunogenic in
the context of a TH2 polarizing adjuvant. During the early phase of
the response (weeks 3–7), the titer differential between D-gp120 and
M-gp120 in Alum was 40–50-fold (pb0.05, one-tailed Student's t
test) although it narrowed over the next 3 months (20- and 7-fold at
weeks 11 and 17) and had disappeared by week 22 (Fig. 4). In
contrast, there was no difference in anti-gp120 titers in mice immu-
nized with D-gp120 or M-gp120 in Quil A, except at week 3 when the
titer in D-gp120 recipients was slightly higher than with M-gp120
(Fig. 4, inset).
Because monomeric gp120 proteins are poor inducers of NAbs
(Burton et al., 2004; Gilbert et al., 2005; Graham et al., 1998) and NAb
responses are generally weak in mice (Burton et al., 2004), we did not
expect to induce any NAbs in these experiments; indeed, their
purpose was to assess inﬂuences on gp120 immunogenicity in
general, not on the induction of NAbs per se. However, for
completeness, we did assess whether sera from the different groups
of gp120-immunized mice differed in their ability to neutralize JR-FL
or MN Env-pseudoviruses (Beddows et al., 2005). As anticipated, NAb
titers to both viruses were extremely low even at the highest serumFig. 2. Antigenic properties of demannosylated gp120. Unmodiﬁed gp120, mannosidase-trea
gp120) were captured onto ELIS plates via Ab D7324, then reacted with serial 3-fold dilution
from duplicatewells. The testMAbs recognize terminal mannoses (2G12); a discontinuous C1
F425-B4e8); or epitopes overlapping the CD4 binding site (CD4BS) (b6, b12, 15e). CD4IgG2 b
HIV-1-infected people.concentration used, and there was no consistent pattern between the
different immunization groups (data not shown).
The D-gp120 (batch #1) preparation contained somemannosidase
protein that survived processing, albeit with minimal enzymatic
activity (Fig. 1B, Table 1). To assess whether the presence of this
additional protein might have an adjuvant effect that increased the
immunogenicity of D-gp120, we prepared a second batch of D-gp120
from which all detectable mannosidase was removed by column
chromatography (Fig. 1B). The immunogenicity of this D-gp120
preparation (batch #2) was compared to M-gp120 in C57BL/6
mice, using Alum as the adjuvant (Fig. 5). Other than a minor
difference in the kinetics of the response to M-gp120 between
weeks 4 and 7, the anti-gp120 antibody proﬁles were similar to
those seen in the previous experiment (see Fig. 4, and also Fig. 6).
The anti-gp120 titers in the D-gp120-immunized mice were again
signiﬁcantly greater (60-fold, at week 8, p=0.0083 using a one-tailed
Student's t test) than in the M-gp120 recipients (Fig. 5). Hence the
increased immunogenicity of D-gp120 results from removal of its
mannose moieties, and not from any adjuvant effect of the enzyme
contaminant.
Blocking the IL-10 receptor increases the antibody response to gp120
in mice
The mannose moieties on gp120 induce the production of IL-10
from humanMDDCs (Shan et al., 2007). Despite the species difference
(mouse vs. humans) and the uncertainty of whether MDDCs resemble
the types of dendritic cell that initiate immune responses to vaccine
antigens, we considered it worthwhile to investigate a possible role
for IL-10 in the differential antibody responses to D-gp120 and M-
gp120 in mice. We therefore administered an IL-10 receptor blocking
MAb (anti-mIL-10R) to mice that were immunized with gp120 in
either Alum or Quil A (this experimentwas carried out simultaneously
with the one described in Fig. 4). An irrelevant MAb of the same
isotype served as a control.
The effect of blocking IL-10 activity during immunization with
gp120 in Alum was similar to that of using D-gp120 instead of gp120
(Fig. 6, compare with Fig. 4). Thus, during the early phase of the
response (weeks 2–7), anti-gp120 IgG titers were approximately 10–
30-fold higher (pb0.05 using a one-tailed Student's t test) in mice
given the anti-mIL-10R MAb than in ones receiving the control MAb
(Fig. 6). The titer differential narrowed beyond 7 weeks, presumably
reﬂecting clearance of the anti-mIL-10R MAb after its last adminis-
tration (at 5 weeks). In contrast, blocking IL-10 activity in mice
receiving gp120 in Quil A had no consistent effect on the anti-gp120
titer (Fig. 6, inset). The localized immunosuppressive effects of gp120-
induced IL-10 expression may, therefore, be responsible for reducing
the antibody response to gp120 in Alum adjuvant, an effect overcome
by removal of the mannoses from gp120, or by changing the adjuvant
to Quil A.
IgG subclass responses to demannosylated and unmodiﬁed gp120s
Wemeasured the endpoint titers of IgG subclasses in sera from the
C57BL/6 mice at week 7, to gauge whether TH1-type (IgG2a and IgG3)
or TH2-type (IgG1) responses were dominant under the different
experimental conditions (Snapper et al., 1992; Stevens et al., 1988).
We also measured IgG2b titers, for which class switching is induced
by TGF-β (McIntyre et al., 1993). There was no induction of gp120-
speciﬁc serum IgA antibodies in any of the groups.ted gp120 (D-gp120, batch #1) or gp120 processed in the absence of mannosidase (M-
s of the antibodies indicated on each panel. The OD490 values displayed are the means
–C4 epitope (A32); a CD4-induced (CD4i) epitope (17b±sCD4); V3 epitopes (447-52D,
inds the CD4Bs and HIVIG is a polyclonal antibody preparation derived from the sera of
Fig. 3. Comparative immunogenicity of D-gp120 in BALB/c mice. Mice (5 per group)
were immunized with gp120, M-gp120 or D-gp120 (batch #1) in Alum (A) or Quil A (B)
adjuvants, as indicated. Anti-gp120 IgG titers were determined using a gp120 capture
ELISA. Each symbol represents the mean (±SEM) reciprocal endpoint anti-gp120 titer
for each group of mice (n=5). Titers b100 (grey shaded area) are considered negative.
The mean reciprocal endpoint titer values for pre-bleed samples were all b1.0×102
(data not shown).
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but not IgG2a, IgG2b or IgG3 (Fig. 7A). This pattern is consistent with
previous reports that the antibody proﬁle to gp120 in mice is strongly
TH2-biased and IgG1-dominated (Daly et al., 2005; Jankovic et al.,
1997; Moore et al., 1999). In addition to inducing ∼60-fold higher
IgG1 titers (p=0.0079 compared to M-gp120), D-gp120 was able
to trigger the production of IgG2a, IgG2b and IgG3 antibodies.
Similar results were obtained when sera from the gp120-, M-gp120
and D-gp120-immunized BALB/c mice were similarly analyzed (data
not shown).
When Quil A was the adjuvant, both gp120s induced binding
antibodies from all four subclasses, the IgG1 and IgG2b titers being
markedly higher than those seen with Alum (Fig. 7B). However, only
the IgG2a titers differed signiﬁcantly between the D-gp120 and M-
gp120 groups (10-fold higher for D-gp120; p=0.00079).
The IgG subclass responses to gp120 in Alum were also measured
in the anti-mIL-10R and isotype control groups at week 7, this being
the last time-point during the early phase at which total IgG titers
were signiﬁcantly elevated in the anti-mIL-10R group (27-fold higher
median, p=0.0079). The median IgG1 titer to gp120 was 15-fold
higher in the anti-mIL-10R recipients (p=0.032) and the IgG3
response was more consistent (3 of 5 mice responding compared to
0 of 4 controls). However, there were no differences in the IgG2a or
IgG2b titers between the two groups (Fig. 8).
To assess whether the use of D-gp120 had changed the IgG
subclass proﬁle in the C57BL/6 mice, or had triggered a generalincrease in all the subclass titers, we calculated the TH1:TH2 index
(IgG2a+IgG3 average titer rank divided by the IgG1 titer rank) for
the anti-gp120 response to each protein-adjuvant combination (see
Materials and methods). This showed that the antibody response to
D-gp120 in Quil A adjuvant was signiﬁcantly less skewed towards a
TH2 proﬁle, compared to the response to M-gp120 (p=0.0087)
(Table 2). For the Alum groups, although TH1-associated IgG2a and
IgG3 anti-gp120 antibodies were detected consistently only in the
mice given D-gp120 (Fig. 7A), the TH1:TH2 indexes were not
signiﬁcantly different between the D- and M-gp120 recipients
(Table 2). The use of the anti-IL-10R MAb did not change the IgG
subclass distribution compared to the isotype control MAb group
(Table 2). Thus IL-10 may be only partially responsible for the
normally TH2-skewed IgG response to gp120.
Blocking IL-10 activity and demannosylating gp120 induce superior
T-cell responses
To measure functional T-cell responses, we used secreted cytokine
assays to assess the in vitro, gp120-speciﬁc recall responses of splenic
T-cells from the C57BL/6 mice. The total numbers of splenic T-cells
(CD3+CD4+ and CD3+CD8+) isolated from the various test groups
were comparable, as measured by ﬂow cytometry (total splenocyte
counts did not vary markedly between groups; data not shown).
Antigen (gp120)-speciﬁc T-cell re-stimulation triggered secretion
of IL-2 and IFN-γ but not IL-4 or IL-10 in vitro, more so in the mice
immunized using Quil A adjuvant than when Alum was used (Figs. 9
and 10). The greater recall response seen using Quil A is consistent
with the known properties of these adjuvants (Sun et al., 2009;
Takahashi et al., 1990). Moreover, T-cells from D-gp120-immunized
mice secreted 2- to 4-fold and 2- to 100-fold more IL-2 and IFN-γ,
respectively, upon gp120 re-stimulation than cells frommice givenM-
gp120, irrespective of the adjuvant (Fig. 9). An anti-CD3 antibody
(polyclonal) stimulus also showed that the general responsiveness of
T-cells from D-gp120-immunizedmicewas signiﬁcantly stronger than
for M-gp120; thus, levels of IL-4, IL-10 and IFN-γ secretion were
elevated by ∼2-fold (Fig. 9). Similar experiments conducted in the
pilot study with BALB/c mice also showed that splenic T-cells from D-
gp120-immunized mice (at week 6) secreted 2- to 8-fold more IL-2
and IFN-γ than cells from mice given either gp120 or M-gp120 (data
not shown).
We also assessed whether inhibiting any IL-10 responses to gp120
in vivo, via use of the receptor blocking MAb, could boost T-cell
responses to gp120. T-cells from mice given gp120 in Alum together
with the anti-mIL-10R MAb had a superior antigen (gp120)-speciﬁc
response, producing signiﬁcantly more IL-2 and IFN-γ than T-cells
from mice receiving the control MAb (Fig. 10). Furthermore, T-cells
from mice in the gp120+anti-mIL-10R MAb (Alum) group also
produced IL-2 (but not IFN-γ) in the absence of antigenic stimulation
(Fig. 10; media). This observation suggests they had become activated
in vivo. Anti-CD3 stimulation also generated stronger cytokine
responses when the in vivo IL-10 response was blocked, irrespective
of the adjuvant. Overall, these studies indicate that T-cell responses in
mice can be improved by immunizing with mannosidase-treated
gp120, which does not induce IL-10 from human MDDC in vitro, or by
blocking the IL-10 receptor via use of a MAb.
Discussion
The purpose of this mouse immunization study was to extend
observations that JR-FL gp120 can induce IL-10 expression from
human MDDC in vitro and impair their ability to activate T-cell
proliferation. Both events are triggered by interactions between gp120
mannose moieties and MCLRs on the MDDC surface, including, but
perhaps not limited to, DC-SIGN (Shan et al., 2007). Accordingly,
removing the terminal mannoses from its N-linked glycans by the use
Fig. 4. Comparative immunogenicity of D-gp120 in C57BL/6 mice. Mice were immunized with M-gp120 (grey symbols) or D-gp120 batch #1 (black symbols) at the times indicated
by the arrows. Main ﬁgure: Alum adjuvant; inset, Quil A adjuvant. Each symbol represents the mean (±SEM) reciprocal endpoint anti-gp120 titer for each group of mice (n=5
initially, but n=4 for M-gp120/Alum from week 7 due to the death of one mouse from an unrelated cause). Titers b100 (grey shaded area) are considered negative.
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functions in vitro (Shan et al., 2007). Because IL-10 can limit the
generation of immune responses by affecting cells involved in
antigen-presentation (APCs) and adaptive immunity (Couper et al.,
2008), we felt it worth exploring whether mannosidase treatment
might improve the immunogenicity of gp120.
We elected to conduct exploratory experiments in mice, both to
compare mannosidase-treated gp120 (D-gp120) with unmodiﬁed
gp120 and to assess whether the use of a blocking MAb to the IL-10
receptor could improve the immune response to unmodiﬁed gp120.
The mouse is not an ideal animal for studying host restrictions on the
immune response to gp120 because the receptor biology differs from
humans; speciﬁcally, gp120 does not recognize murine CD4 or
coreceptors (Clapham and McKnight, 2002; Moore et al., 2004).Fig. 5. The increased immunogenicity of D-gp120 is not due to contaminant
mannosidase. Mice (C57BL/6, 5 per group) were immunized with M-gp120 (grey
symbols) or D-gp120 (batch #2; enyzme free; black symbols) using alum adjuvant, at
the times indicated by the arrows. Each symbol represents themean (±SEM) reciprocal
endpoint anti-gp120 titer for each group of mice. Titers b100 (grey shaded area) are
considered negative.However, as gp120 can bind to various murine MCLRs (Koppel et al.,
2005; Trujillo et al., 2007) and gp120-MCLR interactions are
responsible for the immunosuppressive effects we studied in vitro,
we considered that a mouse experiment was justiﬁed.
We observed that D-gp120 was indeed more immunogenic than
unmodiﬁed gp120, particularly when administered in the TH2-
polarizing adjuvant, Alum. Thus anti-gp120 IgG titers were consis-
tently and markedly (up to 50-fold) higher with the D-gp120
immunogen, and T-cell responses were also improved. The beneﬁcial
effects of mannose removal on IgG titers were not, however, seen
when the adjuvant was switched to Quil A, which is much more TH1-
polarizing than Alum, although stronger T-cell responses to D-gp120
were seen even with Quil A. One other notable effect of mannose
removal was to increase the titers of anti-gp120 antibodies of the less
prevalent IgG subclasses (IgG2a, IgG2b and IgG3). The anti-gp120
response in mice is normally dominated by TH2-associated, IgG1
antibodies (Daly et al., 2005; Jankovic et al., 1997; Moore et al., 1999),
just as we saw in response to unmodiﬁed gp120. However, the TH1-
associated IgG2a and IgG3 subclasses were induced more consistently
to D-gp120 than to unmodiﬁed gp120, particularly in Quil A (in Alum,
all the IgG subclass titers were elevated). Serum gp120-speciﬁc IgA
responses were undetectable in all groups, which was expected
considering that we did not use amucosal immunization protocol. The
cellular immune response assays also showed that the use of D-gp120
improved TH1-associated responses. Hence there are indications that
removing the mannoses from gp120 may partially counteract the
normally strong TH2-dominance of the murine immune response to
this protein. However, additional studies will be required to conﬁrm
this.
One explanation of the improved immune responses to D-gp120 is
that mannose removal alleviates an auto-suppressive response that
normally limits the immunogenicity of unmodiﬁed gp120. Because
gp120 induces mannose-dependent IL-10 expression from human
MDDCs, we investigated whether IL-10 expression might be involved
in restricting the immune response to gp120. Thus, we co-adminis-
tered a blocking MAb to the IL-10 receptor, to antagonize any localized
IL-10-dependent immunosuppressive effects of the gp120 mannose
Fig. 6. Blocking IL-10 activity during immunizationwith gp120 in Alum adjuvant, but not Quil A, increases the anti-gp120 titer in C57BL/6 mice. Mice were immunized with gp120 in
the presence of an anti-mIL-10R MAb (black symbols) or an isotype control MAb (white symbols) at the times indicated by the arrows (black, gp120; grey, MAbs). Main ﬁgure: Alum
adjuvant; inset, Quil A adjuvant. Each symbol represents the mean (±SEM) reciprocal endpoint anti-gp120 titer for each group of mice (n=5 initially, but n=4 for gp120+control
MAb in Alum from week 2 due to the death of one mouse from an unrelated cause). Titers b100 (grey shaded area) are considered negative.
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during the primary phase of the immune response, an effect similar in
kinetics and magnitude to that achieved by using D-gp120 instead of
unmodiﬁed gp120. Hence, IL-10 induction by gp120 may suppress
immune responses to this protein.
The beneﬁcial effects of both mannose removal and the IL-10
receptor MAb on anti-gp120 IgG titers were eventually lost over time,
suggesting that any IL-10-dependent immunosuppressive effect of
gp120 might be restricted to the primary phase of the humoral
response, and inactive during the memory phase. However, both
interventions did inﬂuence memory T-cell responses to gp120,
especially in Alum adjuvant, since we observed differences in IL-2
and IFN-γ expression several months after immunization. Removing
the inﬂuence of IL-10 during primary responses has also been found to
beneﬁt memory T-cell responses in other studies (Biswas et al., 2007;
Foulds et al., 2006).
The anti-IL-10 receptor MAb did not, however, mimic gp120
mannose removal by broadening the anti-gp120 IgG subclass proﬁle,
suggesting that factors other than, or as well as, IL-10 may be involved
in the TH2 polarization of the immune response to gp120. Expressing
IL-12 in mice immunized with gp120 in Alum was found to help
balance the normally TH2-biased response, probably by increasing
the IL-12:IL-10 ratio (Gurney et al., 2005). T-cell responses to a
gp120-expressing DNA vaccine construct were more TH1-polarized in
IL-10−/− mice than in controls, with modestly lower anti-gp120
IgG1 titers and no change in IgG2a (Daly et al., 2005). These
differences between IL-10−/− and control mice were not observed
with an inﬂuenza HA DNA vaccine that induces much more TH1-
polarized responses than gp120. Hence when a response is already
skewed towards TH1, the lack of IL-10 may have little additional effect
(Daly et al., 2005). The TH2-bias of the gp120 response may involve
up-regulating members of the suppressor-of-cytokine-signaling
(SOCS) family in local or inﬁltrating APCs. Thus, IL-10 activatesSOCS-1 and SOCS-3 expression in murine B-cells, and SOCS-1 restricts
the immunostimulatory ability of murine DCs by interfering with IL-
12-dependent responses (Ding et al., 2003; Evel-Kabler et al., 2006).
As a result, SOCS-1 silenced DCs are superior stimulators of gp120-
speciﬁc B and T-cell responses in mice (Song et al., 2006). SOCS-3
expression in murine DCs also promotes TH2-type immune responses
(Li et al., 2006). This aspect of how the immune system sees gp120
warrants further study.
Although we have obtained suggestive evidence that IL-10 is
involved in suppressing immune responses to gp120, we were unable
to detect IL-10 in mouse serum post-vaccination (data not shown).
However, it is more likely that IL-10 would be induced and act locally,
something we now intend to investigate. DCs, macrophages and T-
cells all express the IL-10 receptor and produce IL-10 in vivo (Couper
et al., 2008; Moore et al., 2001). Furthermore, the absence of IL-10
receptor signaling on T-cells, but not DCs, improves T-cell responses to
Listeria monocytogenes antigens in mice (Biswas et al., 2007). Hence,
although our in vitro studies of the IL-10 response to gp120 have
focused on DCs (Shan et al., 2007), other cell types might be involved
in vivo, and IL-10 may act directly on B-cells and T-cells.
In this study, we have shown that the mannose moieties of N-
linked glycans have immunosuppressive effects on responses to HIV-1
gp120 in vivo. There are other examples of mannoses suppressing the
host immune response to pathogens that establish persistent
infections, again mediated via MCLRs. For example, ManLAM and
related mannosylated antigens from M.Tb, Schistosoma spp. eggs,
Leishmania spp. and Helicobacter spp. all bind to DC-SIGN and, in
several cases, induce IL-10 expression (Bergman et al., 2004;
Geijtenbeek et al., 2003; Ghosh and Bandyopadhyay, 2004; van
Liempt et al., 2007). There are also many reports from other viral
infection or vaccination systems of an adverse role for IL-10 in the
development of immune responses, including LCMV, HCV and CMV
(Brady et al., 2003; Brooks et al., 2008; Brooks et al., 2006; Humphreys
Fig. 7. gp120-speciﬁc IgG subclass responses in C57BL/6 mice immunized with M-
gp120 or D-gp120. Serum IgG subclasses were determined 7 weeks after primary
immunization. Shown are reciprocal endpoint titers for each individual mouse
(horizontal bar indicates median values) that received M-gp120 (grey symbols) or D-
gp120 batch #1 (black symbols) in either Alum (panel A) or Quil A (panel B) adjuvants.
Negative responders (titerb100) are shown in the grey boxed area.
Fig. 8. gp120-speciﬁc IgG subclass responses in C57BL/6mice immunized with gp120 in
the presence or absence of an IL-10 receptor MAb. Serum IgG subclasses were
determined 7 weeks after primary immunization. Shown are reciprocal endpoint titers
for each individual mouse (horizontal bar indicates median values) that received gp120
together with an anti-IL-10 receptor MAb (grey symbols) or an isotype control MAb
(black symbols) in Alum adjuvant. Negative responders (titerb100) are shown in the
grey boxed area.
Table 2
IgG subclass response to gp120 immunizations.





Alum M-gp120 – 1.3b 0.082
D-gp120 – 0.9
Quil A M-gp120 – 0.4 0.0087c
D-gp120 – 1.7
Alum gp120 Isotype control 1.8 0.18d
gp120 Anti-mIL-10R 0.6
Quil A gp120 Isotype control 1.3 0.24
gp120 Anti-mIL-10R 1.0
Reciprocal titers in each groupwere ranked in ascending orderwhen the endpoint titers
were ≥100. The TH1:TH2 index was calculated as described in Materials and methods.
a Ranks of reciprocal subclass titers within each adjuvant category (n=11–12) were
entered into the formula to calculate an index for each serum.
b Numbers are medians in each subgroup of mice, n=5–6.
c Signiﬁcant differences by two-tailed comparison are marked in bold.
d Non-parametric comparison, hence the fold difference in absolute medians is not
indicative of, and less important than how much the distributions overlap.
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for persistent viruses and other intracellular pathogens to skew the
host away from the TH1 responses that are considered important for
clearing newly established infections. Thus, although Alum-adju-
vanted inﬂuenza virus antigens induced high antibody titers in mice,
the TH2-biased response was much less protective than a more TH-
balanced one when the mice were challenged with live virus
(Bungener et al., 2008). Whether LCMV, HCV and CMV use mannose
moieties and MCLRs for this purpose remains to be determined, as
there may be multiple ways for the same or different viruses to
achieve the same ends. Various HIV-1 proteins have been reported toinduce IL-10 expression in vitro: Tat suppresses gp120-speciﬁc T-cell
responses through an IL-10-dependent mechanism (Gupta and Mitra,
2007); Nef impairs DC functions (Quaranta et al., 2007) and
stimulates IL-10 release from monocytes (Tangsinmankong et al.,
2002); and the gp41 immunosuppressive peptide region induces IL-10
expression by monocytes (Barcova et al., 1998). It is controversial
whether immunosuppressive effects of IL-10 arise during natural HIV-
1 infection, although elevated IL-10 levels can be detected (Orsilles
et al., 2006; Srikanth et al., 2000). However, dysfunctions of TH-cells
from HIV-1-infected individuals can be reversed by ex-vivo treatment
with anti-IL-10 antibodies (Clerici et al., 1994). Moreover, a high IL-10:
IL-12 ratio has been suggested to promote HIV-1 mucosal transmis-
sion by up-regulating DC-SIGN expression on local antigen-presenting
cells (Gurney et al., 2005).
Our goal in these studies was to explore inﬂuences on the overall
immunogenicity of Env glycoproteins, using monomeric gp120 as a
simple model antigen. Monomeric gp120 is not an effective inducer of
Fig. 9. D-gp120 immunization improves antigen speciﬁc T-cell responses. Unfractionated splenocytes (2.5×105 cells/well) derived from the indicated groups of C57BL/6 mice were
cultured for 72 h with 10 μg/ml of recombinant gp120 (left panel), 2 μg/ml of anti-CD3 (center panel) or media (right panel). Cytokine levels in supernatants from triplicate wells
were measured by ELISA and are expressed in pg/ml as the mean value±SD above the respective assay detection limits. The mice were immunized with M-gp120 (white bars) or D-
gp120 batch #1 (black bars) in the adjuvant indicated at the foot of the ﬁgure. ⁎pb0.05 (one-tailed Student's t test).
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fore, not surprised when no NAbs were detected in the mouse sera.
Mannose depletion alone would be unlikely to overcome the many
limitations to the immunogenicity of monomeric gp120, which have a
basis in Env structure (Karlsson Hedestam et al., 2008; Pantophlet and
Burton, 2006). Complex carbohydrates are unaffected bymannosidase
treatment. Thus, most of the carbohydrate chains that occlude the
underlying protein epitopes and which contribute to the limited
immunogenicity of gp120 are still intact.
Of note is that the ∼10 kDa reduction in the m.wt. of gp120 after
mannosidase treatment corresponds to the removal of ∼55 mannose
residues. Although the number of high-mannose glycan structures on
JR-FL gp120 is unknown, there are 11 such structures on IIIB gp120
(Leonard et al., 1990). Each of these oligomannose glycans contain 4–8
α1-2, α1-3 and α1-6-linked mannose moieties that are susceptible to
removal by α(1-2,3,6)-mannosidase. Hence there are probably
between 44 and 88 theoretically vulnerable mannose residues on
IIIB gp120, and the number on JR-FL gp120 is likely to be similar. Our
observed m.wt. reduction of ∼10 kDa (∼55 mannoses) implies that a
majority of the vulnerable mannoses are removed, but some may
remain. However, here and elsewhere, we show that mannosidase
treatment abolishes the binding of 2G12 and DC-SIGN to gp120
(Sanders et al., 2002; Shan et al., 2007). The surface-exposedmannoseresidues most involved in ligand binding have therefore been
removed; investigating the consequences for the immunogenicity of
gp120 was principal goal of the present study.
An effective vaccine will require the induction of NAbs to primary
isolates, not just the gp120-binding antibodies we have measured
here (Walker and Burton, 2008). Similarly, the detection of IL-2 or IFN-
γ expression by T-cells does not prove that these cells have functional
T-helper or CTL activity (Walker and Burton, 2008). However, if and
when new immunogens, perhaps ones based on Env trimers, are
developed that can induce NAbs efﬁciently, knowing how to present
them effectively to the human immune system will be important. All
things being equal, if an Env antigen is developed that can induce
NAbs, increasing its overall immunogenicity, for example by mannose
removal, could be advantageous. This may be particularly so if the
intervention has a dose-sparing effect on an Env antigen that is
difﬁcult to make in bulk. Using effective adjuvants can help, but some
adjuvants (e.g., those containing detergents) may be incompatible
with preserving the appropriate Env antigen conﬁguration. Hence, it is
relevant that the most substantially improved humoral and cellular
responses to demannosylated gp120 were seenwith Alum, a routinely
used adjuvant. Moreover, the auto-suppressive effects of gp120
mannoses on anti-gp120 responses might extend to any other co-
administered antigens in the context of a multivalent vaccine,
Fig. 10. Antigen-speciﬁc T-cell responses from gp120-immunized C57BL/6 mice. Unfractionated splenocytes (2.5×105 cells/well) derived from the indicated groups of C57BL/6 mice
were cultured for 72 h with 10 μg/ml of recombinant gp120 (left panel), 2 μg/ml of anti-CD3 (center panel) or media (right panel). Cytokine levels in supernatants from triplicate
wells were measured by ELISA and are expressed in pg/ml as the mean value±SD (the y-axis starts at the manufacturer speciﬁed detection limit for each cytokine). The mice were
immunized with gp120 in the adjuvant indicated at the foot of the ﬁgure, and in the presence of an isotype control MAb (white bars) or the anti-mIL-10R MAb (black bars). ⁎pb0.05
(one-tailed Student's t test).
117K. Banerjee et al. / Virology 389 (2009) 108–121particularly those intended to induce T-cell responses. We are
presently assessing how to remove the mannose moieties from Env
trimers without compromising trimer stability or conformation, with
the goal of performing immunogenicity studies to determine whether
mannose-mediated suppression of the immune response also occurs
with these more vaccine-relevant forms of HIV-1 Env antigens.
Materials and methods
Mannosidase treatment of gp120 proteins
Recombinant, Chinese hamster ovary (CHO) cell expressed mono-
meric gp120 from HIV-1 JR-FL was prepared under pyrogen-free
conditions and was enzymatically demannosylated (to make D-
gp120) as previously described, with minor modiﬁcations (Sanders
et al., 2002; Shan et al., 2007). Brieﬂy, gp120 was treated with Jack
beanα(1-2,3,6)-mannosidase (ProZyme Inc, San Leandro, CA) for 18 h
at 37 °C in the presence of protease inhibitors, before being exchanged
into half-strength PBS using a 30 kDa molecular weight cutoff spin
ﬁlter (Sartorius, NY). The outcome of the digests was analyzed using a
non-reducing 4–12% Bis–Tris NuPage gel system (Invitrogen, CA), and
an enzyme activity assay (see below). A control preparation (M-gp120) was made by processing gp120 under identical conditions to
D-gp120 batch #1, but without the addition of the mannosidase
enzyme. To removemannosidasewhenmaking D-gp120 batch #2, the
standard D-gp120 preparation was passed through a ceramic hydro-
xylapatite (CHT) column (BioRad Laboratory, CA).
Endotoxin was removed from the various gp120 preparations
using the Endofree Red 5/1 kit (Profos AG, Regensberg, Germany); the
resulting endotoxin levels were below the detection limit of the LAL
test (0.06 EU/ml). To speciﬁcally determine gp120 protein concentra-
tions in various preparations (after the enzyme reactions, and before
and after the CHT column puriﬁcation), we used both a bicinchoninic
acid assay (Pierce Protein Research Products, Thermo Fisher Scientiﬁc,
Rockford, IL) and SDS-PAGE densitometry.
Analysis of mannosidase activity
The residual Jack bean α(1-2,3,6)-mannosidase activity in D-
gp120 preparations was determined using an enzymatic activity assay,
following the manufacturer's protocol (Prozyme) with some mod-
iﬁcations. Brieﬂy, 0.4 ml of substrate solution, pre-warmed to 37 °C,
was added to each tube. Then 5 μl of samples, or different
concentrations of α(1-2,3,6)-mannosidase standards, were added
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carbonate and measurement of the absorbance at 400 nm using a
spectrophotometer. The residual enzymatic activity in the D-gp120
preparations was determined using the standard curve derived using
known enzyme concentrations. One unit ofα(1-2,3,6) mannosidase is
deﬁned as the amount of enzyme required to hydrolyze 1 μmol of p-
nitrophenol (Sigma, MO) in 1 min at 37 °C, pH 5.0. The activity of
enzyme added to the reactionmixture at the start of the demannosyla-
tion procedure was deﬁned as 100% for normalization purposes; this
corresponded to 14.2 U/mg gp120 protein or 1.42 U/ml (see Table 1).
The assay detection limit was 0.01 U/ml.
Monoclonal antibodies (MAbs)
MAb 2G12 to a mannose-dependent gp120 epitope (Buchacher et
al., 1994; Scanlan et al., 2002; Trkola et al.,1996) was obtained fromDr.
Hermann Katinger, University of Natural Resources and Applied Life
Sciences, Vienna. MAbs 17b to the CD4i site on gp120 (Thali et al.,
1993), A32 to a gp120 C1–C4 epitope (Moore et al., 1994; Wyatt et al.,
1995), and 15e (Robinson et al., 1990), b6 (Parren et al., 1997) and b12
(Burton et al., 1991) to CD4BS-associated gp120 epitopes were all
obtained from the reagent repository of IAVI's Neutralizing Antibody
Consortium. MAbs F425-B4e8 (Cavacini et al., 2003) and 447-52D
(Gorny et al., 1992) to gp120 V3 epitopes (contributed by L. Cavacini
and S. Zolla-Pazner respectively) and pooled serum from HIV-1
infected individuals (HIVIG) were obtained from the NIH AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID,
NIH. CD4-IgG2 (PRO 542) and soluble CD4 were manufactured at
Progenics Phramceuticals. Inc. (Allaway et al., 1993). All the above
MAbs are of human origin, and CD4-IgG2 contains a human Ig Fc
region.
MAb reactivity with gp120 and demannosylated gp120
The gp120-capture enzyme-linked immunosorbent assay
(ELISA) procedure using the sheep Ab D7324 to the gp120 C-
terminus has been described previously (Moore and Jarrett, 1988;
Moore and Sodroski, 1996) (see below). The starting concentrations
for 3-fold serial dilutions of the test MAbs were: 1 μg/ml (2G12,
17b, A32, 15e, b6, b12, CD4-IgG2); 0.75 μg/ml (F425-B4e8); 2 μl/ml
(447-52D). To each dilution of 17b, 300 ng/ml of soluble CD4 was
added. For HIVIG, the starting concentration was 10 μg/ml. All
assays were performed using duplicate wells. The data were
plotted using Graph Pad Prism software (sigmoidal curve with
variable slope, bottom constraint zero). Wells receiving serum but
no gp120 were used to derive background OD values that were
subtracted from test values.
Immunization of mice with gp120, and use of anti-mIL-10R MAb
Eight-week old, female BALB/c and C57BL/6 mice were purchased
from Charles River Laboratories, Wilmington, MA. All experimental
procedures were conducted in accordancewith protocols approved by
the relevant Institutional Animal Care and Use Committees.
In the pilot experiment, BALB/c mice (5 per arm) were immunized
at weeks 0, 2 and 4 and bled at weeks 2, 4 and 6. In the later
experiments, C57BL/6 mice (5 per arm) were immunized at weeks 0,
2, 5 and 20, and bled at weeks 1, 2, 3, 5, 7, 11, 17 and 22. In all
experiments, a 130 μl formulation containing 5 μg of gp120, M-gp120
or D-gp120, and either 10 μg of Quil A (saponin derived from the bark
of Quillaja saponaria (Aguilar and Rodriguez, 2007), Accurate
Chemical, Westbury, NY) or 250 μg of Alum adjuvant (Aguilar and
Rodriguez, 2007; Eisenbarth et al., 2008; Kool et al., 2008; Seubert et
al., 2008) (Alhydrogel; Accurate Chemical, Westbury, NY) was
injected subcutaneously into the groin region. Primary and boosting
immunizations were carried out identically.In the IL-10 blocking studies, the mice were injected intra-
peritoneally with 500 μg of an anti-mIL-10R MAb or an isotype
control MAb (Brooks et al., 2008; Brooks et al., 2006), one day prior to
the gp120 immunizations at 0, 2 and 5 weeks, but not prior to the
fourth immunization at week 20. The puriﬁed, no-azide/low-
endotoxin (NA/LE), rat anti-mouse IL-10 receptor blocking MAb
(anti-mIL-10R, Clone 1B1.3a, Cat# 550012) and the isotype-matched
control MAb (Clone R3-34, Cat#553922) were purchased from BD
Biosciences.
After blood was drawn, it was allowed to clot for 1 h at room
temperature. Serum was then collected, and stored in aliquots at
−20 °C. Splenocytes were obtained post mortem, pooled for each
group and processed to make single cell suspensions in RPMI plus 10%
FCS and 10% DMSO, and stored in liquid nitrogen.
Enzyme linked immunosorbent assays (ELISA) for anti-gp120 total IgG,
IgA and IgG subclasses in mouse sera
The gp120-capture ELISA procedure has been described previously
(Moore and Jarrett, 1988; Moore and Sodroski, 1996). Brieﬂy, the
plates were coated with 10 μg/ml of sheep Ab D7324 to the gp120 C-
terminus (Cliniqa Corp, San Marcos, CA, Cat. #6205). Recombinant,
CHO-cell expressed JR-FL gp120 (300 ng/ml in TBS) was then
captured onto the bound D7324. In an alternative procedure (used
for gp120-binding IgG2a Abs, see below), ELISA wells were directly
coated with gp120 (5 μg/ml in carbonate buffer overnight). Mouse
serum (3-fold serial dilutions from 1:100) was then added, followed
by a suitable dilution of an alkaline phosphatase (AP)-conjugated
detection antibody. The AMPAK Enzyme Ampliﬁcation Kit (Dakocy-
tomation, Ely, UK) was used to provide a colorimetric endpoint. The
plates were read at 490 nm on an E max precision microplate reader
(Molecular Devices, Sunnyvale, CA).
The detection antibodies for total IgG, IgG2a and IgA were AP-
conjugated polyclonal goat anti-mouse IgG and anti-mouse IgG2a
(1:2000; AbD Serotec, Oxford, UK; Cat# STAR117A and STAR 82A,
respectively) and goat anti-mouse IgA (1:500; Southern Biotech,
Birmingham, AL; Cat#1040-04). To detect IgG1, IgG2b and IgG3 Abs,
we ﬁrst used unconjugated rat anti-mouse IgG1 (AbD Serotec,
Cat#MCA1289), IgG2b (BD Biosciences, Cat#553392) and IgG3 (AbD
Serotec, Cat#MCA1292). The gp120-bound IgG1, IgG2b and IgG3 Abs
were then detected using a 1:30,000 dilution of AP-conjugated rabbit
anti-rat IgG (Sigma, Cat #A6066), a reagent we conﬁrmed to be
reactive with neither mouse IgG nor the sheep D7324 capture Ab.
Prior to testing mouse serum samples, the anti-mouse IgG1, IgG2a,
IgG2b and IgG3 detection antibodies were assessed for cross-
reactivity and speciﬁcity using authentic mouse IgG1, IgG2a, IgG2b
and IgG3MAbs (BD Biosciences). A preliminary test was conducted by
directly coating these MAbs (1 μg/ml) onto ELISA plate wells. The
plates were washed with PBS plus 0.1% Tween. Well-blocking and
antibody dilution procedures were carried out using PBS plus 10% FCS.
The anti-mouse IgG1 was tested at 0.5, 1 and 2 μg/ml, anti-mouse
IgG2a at dilutions of 1:1000, 1:2000 and 1:4000, anti-mouse IgG2b at
dilutions of 1, 2 and 4 μg/ml, and anti-mouse IgG3 at dilutions of 2.5, 5
and 10 μg/ml. The optimal concentrations that provided acceptable
sensitivity and minimal cross-reactivity were found to be: 1 μg/ml of
anti-mouse IgG1, a 1:2000 dilution of anti-mouse IgG2a, 2.5 μg/ml of
anti-mouse IgG2b and 2.5 μg/ml of anti-mouse IgG3.
The same MAbs were then tested for cross-reactivity with the
sheep D7324 capture Ab, coated onto ELISA plate wells as described
above The anti-mouse IgG1, IgG2b and IgG3 antibodies did not cross-
react signiﬁcantly with D7324, but the anti-mouse IgG2a did react
signiﬁcantly, precluding its use in the standard gp120-capture ELISA.
The alternative procedure of coating the ELISA wells directly with
gp120 was therefore used for detection of anti-IgG2a Abs (see above).
To calculate endpoint titers, background OD values (wells
without gp120 but with the lowest serum dilution) were subtracted
119K. Banerjee et al. / Virology 389 (2009) 108–121from OD values derived from test wells that contained both gp120
and serum. The resulting values were plotted on Graphpad Prism
software (sigmoidal curve with variable slope, bottom constraint
zero). The formula used for titer calculations was X=logEC50−([log
(TOP/Y−1)/Hillslope]) where Y=5 SD of 3 background wells
receiving gp120 but no serum and X=log[serum dilution] (logEC50,
TOP and Hillslope calculated by the Graphpad Prism software). Sera
with extrapolated reciprocal titer values below 1.0×102 (1:100 serum
dilution) or ones generating graphs with poor R2 values (below 0.7)
were considered negative for the Ab being detected.
Calculation of TH1:TH2 index
To determine whether gp120 demannosylation or IL-10-receptor
blockade affected the relative amounts of anti-gp120 Abs from IgG
subclasses that are linked to TH1 (IgG2a and IgG3) and TH2 (IgG1)
polarization, we proceeded as follows. The reciprocal IgG subclass
titers for each mouse were ranked from one to four in ascending order
and then summed across the mice of each test group (titersb1.0×102
were considered negative and excluded from the analysis). Based on
the summed values, the TH1:TH2 index was then calculated as ([IgG2a
rank+IgG3 rank]/2)/(IgG1 rank). The higher the resulting value, the
more polarized the antibody response towards TH1-associated
subclasses. Although we also measured IgG2b titers, we excluded
them from the titer index calculation because of controversies about
the precise relationship between this IgG subclass and TH-polarization
(McIntyre et al., 1993; Weiner, 2001).
HIV-1 neutralization assay
A single round Env-pseudovirus assay involving theU87/CD4.CCR5
andU87/CD4.CXCR4 cell lineswasused to test the ability ofmouse sera
to neutralize HIV-1, as described previously but with minor modiﬁca-
tions (Binley et al., 2004). Luciferase-expressing, Env-pseudotyped
virus stocks based on the homologous, neutralization-resistant R5 Env
JR-FL and the neutralization sensitive X4 Env MN were made as
described previously (Beddows et al., 2005). The pseudoviruses were
then incubated for 1 h at 37 °C with serial fourfold dilutions of heat-
inactivated (56 °C for 30min)mouse serum, starting at a 1:20 dilution.
CD4-IgG2 (1 μg/ml) served as a positive control. Virus and sera were
then added to the target cells (plated 24 h earlier in ﬂat-bottom, 96-
well plates at 3×103 cells/well). Inhibition of infectivity was
determined 72 h post-inoculation by measuring luciferase activity
(in counts-per-second, cps). Inhibition of infection for a given dilution
of serum (normalized to pre-bleed sera from the same mouse) was
calculated using the formula {[1−(a−c)/(b−c)]}×100, where
a=cps for cell+virus+serum from immunized mouse, b=cps for
cell+virus+serum from pre-bleedmouse, c=cells only (Beddows et
al., 2005).
T-cell functional assays
In vitro re-stimulation of T-cells (CD4+ and CD8+ combined) in
unfractionated splenocyte cultures was carried out by culturing
2.5×105 cells/well (in triplicate) with JR-FL gp120 (10 μg/ml) in a
ﬁnal volume of 200 μl/well. Positive control wells received an anti-
CD3e antibody (2 μg/ml, BD Biosciences, Clone 145-2C11, Cat 553057),
negative control wells received media. Supernatants were collected
after a 72 h culture at 37 °C in 5% CO2 and stored at−80 °C till further
use. Concentrations of IL-2, IL-4, IL-10 and IFNγ in the supernatants
were measured by a sandwich ELISA, according to the manufacturer's
instructions (OptEIA mouse ELISA kits, BD Biosciences), with a ™B
substrate kit (BD Biosciences) used to provide a colorimetric endpoint
at 405 nm. The assay sensitivity limits were approximately 4 pg/ml for
IL-2, 10 pg/ml for IL-4, and 30 pg/ml for IL-10 and IFNγ. Cytokine
levels were expressed in pg/ml above the respective assay detectionlimits and graphs plotted to show the mean value±SD for triplicate
wells.
Flow cytometry
The numbers of T-cells in spleens of immunized mice were
determined using standard cell surface staining protocols and an LSR-
II ﬂow cytometer (BD Biosciences). The resulting data were analyzed
using FlowJo software (Version 7.2, Tree Star Inc. Ashland, OR). All
antibodies were purchased from BD Biosciences. Surface staining was
carried out in a PBS+10% FBS buffer for 20 min, followed by 2 washes
with the same buffer. Prior to staining for speciﬁc cell surface markers,
Fc receptors were blocked with an anti-mouse CD16/CD32 antibody
(clone 2.4G2). The following labeled antibodies speciﬁc for mouse T-
cell markers were used: TCRβ-APC (clone H57-597), CD3 APC (clone
145-2C11), CD4 PCP (clone RM4-5), CD8 PE (clone 53-6.7).
Statistical analyses
A one-tailed Mann–Whitney U test was employed for statistical
analysis of data unless otherwise mentioned.
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